Arrowhead Pharmaceuticals (ARWR) Upgraded by ValuEngine to Sell

ValuEngine upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a strong sell rating to a sell rating in a research report sent to investors on Thursday.

ARWR has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed a hold rating and issued a $2.00 target price (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a research report on Monday, September 18th. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 target price on the stock in a research report on Monday, November 27th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Jefferies Group reaffirmed a hold rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $3.17.

Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at $3.49 on Thursday. Arrowhead Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $4.54. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in Arrowhead Pharmaceuticals by 3.7% in the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after buying an additional 11,099 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the period. Geode Capital Management LLC increased its stake in Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 21,654 shares during the period. Dimensional Fund Advisors LP increased its stake in Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 31,765 shares during the period. Finally, Virtu KCG Holdings LLC increased its stake in Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares during the period. 20.20% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) Upgraded by ValuEngine to Sell” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/04/arrowhead-pharmaceuticals-arwr-upgraded-by-valuengine-to-sell.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What are top analysts saying about Arrowhead Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arrowhead Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit